Dimensional Fund Advisors LP Mersana Therapeutics, Inc. Transaction History

Dimensional Fund Advisors LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$2.0 - $4.45 $35,080 - $78,053	-17,540 Reduced 56.14%	13,703 $27,000
Q1 2024 May 10, 2024	SELL	$2.16 - $5.94 $152,111 - $418,306	-70,422 Reduced 69.27%	31,243 $139,000
Q4 2023 Feb 07, 2024	SELL	$1.11 - $2.34 $11,713 - $24,694	-10,553 Reduced 9.4%	101,665 $235,000
Q3 2023 Nov 09, 2023	SELL	$1.06 - $3.91 $82,036 - $302,606	-77,393 Reduced 40.82%	112,218 $142,000
Q2 2023 Aug 09, 2023	SELL	$3.08 - $9.55 $707,556 - $2.19 Million	-229,726 Reduced 54.78%	189,611 $623,000
Q1 2023 May 12, 2023	SELL	$4.0 - $7.02 $281,784 - $494,530	-70,446 Reduced 14.38%	419,337 $1.72 Million
Q4 2022 Feb 09, 2023	SELL	$5.65 - $7.86 $15,283 - $21,261	-2,705 Reduced 0.55%	489,783 $2.87 Million
Q3 2022 Nov 10, 2022	BUY	$4.63 - $8.0 $1.31 Million - $2.27 Million	283,428 Added 135.57%	492,488 $3.33 Million
Q2 2022 Aug 12, 2022	BUY	$2.84 - $5.0 $65,376 - $115,100	23,020 Added 12.37%	209,060 $965,000
Q1 2022 May 13, 2022	SELL	$3.74 - $6.63 $31,700 - $56,195	-8,476 Reduced 4.36%	186,040 $742,000
Q4 2021 Feb 09, 2022	BUY	$5.48 - $9.86 $38,360 - $69,020	7,000 Added 3.73%	194,516 $1.21 Million
Q3 2021 Nov 12, 2021	BUY	$8.56 - $14.47 $98,542 - $166,578	11,512 Added 6.54%	187,516 $1.77 Million
Q2 2021 Aug 12, 2021	SELL	$13.28 - $18.07 $37,701 - $51,300	-2,839 Reduced 1.59%	176,004 $2.39 Million
Q1 2021 May 14, 2021	SELL	$15.31 - $26.52 $49,068 - $84,996	-3,205 Reduced 1.76%	178,843 $2.89 Million
Q4 2020 Feb 25, 2021	BUY	$16.84 - $27.59 $3.07 Million - $5.02 Million	182,048 New	182,048 $4.84 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.